- Home
- LX vs PHAR Comparison
LX vs PHAR Comparison
Compare LX & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LX
- PHAR
- Stock Information
- Founded
- LX 2013
- PHAR 1988
- Country
- LX China
- PHAR Netherlands
- Employees
- LX N/A
- PHAR N/A
- Industry
- LX Finance: Consumer Services
- PHAR Biotechnology: Pharmaceutical Preparations
- Sector
- LX Finance
- PHAR Health Care
- Exchange
- LX Nasdaq
- PHAR Nasdaq
- Market Cap
- LX 1.1B
- PHAR 951.7M
- IPO Year
- LX 2017
- PHAR N/A
- Fundamental
- Price
- LX $5.08
- PHAR $14.55
- Analyst Decision
- LX
- PHAR Strong Buy
- Analyst Count
- LX 0
- PHAR 3
- Target Price
- LX N/A
- PHAR $30.00
- AVG Volume (30 Days)
- LX 2.8M
- PHAR 14.4K
- Earning Date
- LX 11-24-2025
- PHAR 10-23-2025
- Dividend Yield
- LX 7.72%
- PHAR N/A
- EPS Growth
- LX 86.38
- PHAR N/A
- EPS
- LX 1.28
- PHAR N/A
- Revenue
- LX $1,956,013,429.00
- PHAR $339,836,000.00
- Revenue This Year
- LX $6.40
- PHAR $17.44
- Revenue Next Year
- LX $17.75
- PHAR $8.46
- P/E Ratio
- LX $4.15
- PHAR N/A
- Revenue Growth
- LX 0.80
- PHAR 22.44
- 52 Week Low
- LX $2.63
- PHAR $7.31
- 52 Week High
- LX $11.64
- PHAR $17.08
- Technical
- Relative Strength Index (RSI)
- LX 33.01
- PHAR 51.90
- Support Level
- LX $5.27
- PHAR $13.18
- Resistance Level
- LX $5.79
- PHAR $16.29
- Average True Range (ATR)
- LX 0.21
- PHAR 0.55
- MACD
- LX -0.02
- PHAR -0.04
- Stochastic Oscillator
- LX 0.14
- PHAR 44.05
About LX LexinFintech Holdings Ltd.
LexinFintech Holdings Ltd is an online consumer finance platform and a technology-driven service provider in China. The group is engaged in online direct sales services and online consumer finance services for its customers in the PRC. Geographically, it derives revenue from China.
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.